Speaker
Summary
The United States is a global leader in nuclear technology, yet access to key medical isotopes remain fragile due to limited global production capacity, reliance on foreign reactors, and short isotopes half-lives. To address this, we have developed the first ML-driven Medical Isotope Planning Digital Twin (MIP-DT) to optimize nuclear reactor-based production of medical isotopes. Our goal is to increase isotope yield and throughput directly, supporting access to lifesaving diagnostics and therapies for cancer, cardiovascular, and neurological diseases. This work evaluates a series of irradiation scenarios for Sm-152 at UT Austin’s TRIGA Mk-II reactor. The objective was to ensure safe reactor operations while producing the target activity of Sm-153 required for a 150 mCi patent dose.
| Are you interested/eligible for the Young Session? | Yes, I am eligible and interested in participating |
|---|
